Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 7 (all of which have been updated or confirmed before the report)
| KPI (MSEK, unless otherwise specified) | Q3 2026E |
| Net sales | 238 |
| Organic growth in local currency (%) | 25.03 |
| Gross profit | 171 |
| EBITDA | 45.8 |
| EBIT | 22.9 |
| Net profit | 17.2 |
| Earnings per share (SEK) | 0.54 |
XVIVO Perfusion’s Q3 report will be released on Thursday 22 October at 07.30 CEST.